顺铂、紫杉醇在复治非小细胞肺癌中的近期疗效观察  

Efficacy of refractory non small cell lung cancer Patients treated with taxel and cisplatin

作　　者：孙君重[1] 殷明君[1] 胡玉兰[1] 

机构地区：[1]河南省南阳市第一人民医院肿瘤科

出　　处：《肿瘤防治研究》1999年第3期205-206,共2页Cancer Research on Prevention and Treatment

摘　　要：目的：为了寻找非小细胞肺癌的有效治疗方法。方法：本组研究对２１例对ＣＡＰ、ＥＰ、ＮＶＢＰ、ＶＤＳＰ等方案耐药的非小细胞肺癌患者，采用顺铂、紫杉醇治疗。经２～３个周期治疗，进行疗效和毒副作用评价。结果：按照ＷＨＯ标准，总有效率（ＣＲ＋ＰＲ）为３５０％（７／２０）。７例有效者均为ＰＲ，主要毒副作用为白细胞和血小板下降，脱发、肌肉／关节疼痛，ⅢⅣ级白细胞和血小板下降并不多见，毒副作用可以耐受。结论：表明本方案对耐药性ＮＳＣＬＣ仍然有效。In order to search the effectiveness of Taxel+Cisplatin in patients with non small cell lung cancer (NSCLC),from May 1995 to November 1997,21 cases of NSCLC patients were treated with the combination regimen of taxel and cisplatin.All patients were resistant to several kinds of chemotherapeutic protocols such as CAP,EP,NVB P or VDS P.After two courses of treatment,their efficiency and toxicity were evaluated according to the WHO's criteria,the ovreall response rate(CR+PR)was 35 0%(7/20)with no CR and seven PR.The major toxicity were descent WBC and platelet counts,diarrhea,myalgia/arthralgia.However,Ⅲ Ⅳ grade of neutropenia and thrombocytopenia were rare observed,and most of them were tolerable.We think this protocol is safe and effective for resistant NSCLC patients.

关 键 词：非小细胞肺癌 顺铂 紫杉醇 肺肿瘤 药物疗法 

分 类 号：R734.205[医药卫生—肿瘤]